BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30
• 31

• 

  Business

  A Look at A Few Hot New Approaches and News in the Research Imaging Market

  Advances in data storage and processing, as well as biomarker identification, has led to cutting-edge breakthroughs in clinical and research imaging technology. Here’s a look at just a few of these stories.

  May 31, 2018

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  FDA Chains Clinical Hold on CRISPR/ Vertex Sickle Cell Disease IND

  Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.

  May 31, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Policy

  President Trump Signs ‘Right to Try Act’ Into Law

  President Donald Trump signed the recently-passed ‘Right to Try Act,’ which will give terminally ill patients the right to seek access to medications that have yet to be approved in order to save their lives.

  May 31, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Madrigal Pharma’s NASH Drug Has Positive Results in Phase II

  Madrigal Pharmaceuticals announced positive topline data from its Phase II clinical trial of MGL-3196 in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).

  May 31, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Primary Endpoint Hit: Gilead and Galapagos’ JAK1 Inhibitor for Arthritis Positive in Phase II

  Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.

  May 31, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  U.S. Justice Department Gives Bayer and Monsanto Go-Ahead for Merger

  U.S. Justice Department gave the merger the go-ahead after Monsanto agreed to sell approximately $9 billion in assets.

  May 31, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Alzheimer’s Company Cortexyme Closes $76 Million Series B Financing Round with Pfizer, Takeda and Google Participating

  South San Francisco-based Cortexyme closed on a $76 million Series B financing round.

  May 31, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Nektar Therapeutics’ Big Week: Syndax Cancer Collaboration and New Opioid Submission

  It’s been a busy week for Nektar Therapeutics with the announcement of an NDA submission to the FDA for NKTR-181 and a non-exclusive, clinical collaboration deal with Syndax Pharmaceuticals.

  May 31, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Beach

  June 1st Research Roundup

  There are plenty of great scientific research stories out this week from a tool to delete gene products to the growth of whole muscles incorporated into a biohybrid robot. Here’s a look at just a few of them.

  May 31, 2018

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Johnson & Johnson’s Esketamine Shows Promise in Depression Clinical Trials

  The Janssen Pharmaceutical Companies, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray.

  May 31, 2018

   · 

  3 min read

   · 

  Mark Terry